Curia, a leading global contract development and manufacturing organization (CDMO), is expanding its pharmaceutical manufacturing capacity in Glasgow, United Kingdom, and enhancing its cell line development platform. The investments, announced on March 19, 2026, aim to bolster the company’s capabilities in sterile fill-finish and accelerate the development of novel therapies for its partners. This expansion reflects a broader trend in the pharmaceutical industry towards outsourcing manufacturing and development to specialized CDMOs like Curia, as companies seek to streamline operations and focus on core competencies.
The Glasgow site has a long-standing reputation within the industry, with over 25 years of experience in formulation, lyophilization development, and sterile fill-finish capabilities, including handling highly potent products like antibody-drug conjugates (ADCs). The current expansion, slated for completion in early 2027, will add an isolator-based vial filling line compliant with Annex 1 standards, as well as a lyophilizer. Once operational, the Glasgow facility will be able to fill batches of up to 20,000 vials, positioning it to support future compact-scale commercial fills.
“This expansion in Glasgow comes as Curia nears completion of our significant expansion at the commercial pharmaceutical manufacturing plant in Albuquerque, New Mexico,” said Ron Aungst, Vice President of Operations for Pharmaceutical Business Units. “Curia has already secured crucial equipment with long lead times to maintain the Glasgow expansion project on track, and we do not anticipate any disruption to current operations during the expansion.” This coordinated expansion strategy highlights Curia’s commitment to increasing capacity and meeting growing demand from its pharmaceutical partners.
Advancing Cell Line Development Capabilities
Beyond the Glasgow expansion, Curia is as well making strides in its clinical pharmaceutical substance development capabilities through advancements in its proprietary cell line development (CLD) platform. The CLD offering at Curia’s Hopkinton, Massachusetts facility has been optimized to incorporate non-proprietary, semi-directed integration technology, resulting in six times higher titers compared to random integration technology. This improvement translates to increased efficiency and productivity in the development of cell lines for biopharmaceutical production.
Curia’s stable platform, CHO-GSN®, is derived from the same parental cell line as its transient platform, TunaCHO®, enabling partners to effectively scale from discovery through GMP manufacturing. This seamless transition is a key advantage for companies looking to accelerate their drug development programs. The ability to efficiently scale production is critical in reducing timelines and costs associated with bringing new therapies to market.
A Platform for Biologics Innovation
“Our biologics division has always had end-to-end capabilities, and we are excited to offer a cell line that makes it more cost-effective and faster to advance partners through early-stage clinical manufacturing,” said Jamie Grabowski, President of Research and Development. “With favorable licensing terms for biotechnology companies, the redesigned cell line will be a critical component in successfully guiding partners along their path to commercialization.” The new cell line is designed to address the specific needs of biotech companies, offering a streamlined and affordable pathway to clinical development.
The improvements to Curia’s CLD platform are particularly significant in the context of the growing biologics market. Biologics, which include antibodies, proteins, and other complex molecules, are becoming increasingly important in the treatment of a wide range of diseases. Efficient and cost-effective manufacturing of biologics is therefore essential for ensuring access to these life-saving therapies. The company operates an integrated network of 23 facilities and employs over 3,500 professionals across North America, Europe, and India, according to information on their website curiaglobal.com.
About Curia
Curia is a contract research, development, and manufacturing organization (CDMO) with over 30 years of experience. The company collaborates with biopharmaceutical clients to bring innovative therapies to market, offering services spanning small molecules, generic APIs, and biologics, from discovery to commercialization. Curia’s integrated capabilities include regulatory support, analytical testing, and sterile fill-finish.
Contact:
Viana Bhagan
Curia
+1 518 512 2111
[email protected]
Curia’s ongoing investments in both manufacturing capacity and technology platforms demonstrate its commitment to supporting the pharmaceutical industry’s efforts to develop and deliver innovative therapies. The completion of the Glasgow expansion and the continued refinement of the CLD platform are expected to further enhance Curia’s position as a leading CDMO. The company anticipates providing further updates on the Albuquerque expansion project in the coming months, with a projected completion date later in 2026.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical or investment advice.
